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Vancomycin-resistant enterococci (VRE) have caused
hospital outbreaks worldwide, and the vancomycin-resist-
ance gene (vanA) has crossed genus boundaries to methi-
cillin-resistant  Staphylococcus aureus. Spread of VRE,
therefore, represents an immediate threat for patient care
and creates a reservoir of mobile resistance genes for
other, more virulent pathogens. Evolutionary genetics, pop-
ulation structure, and geographic distribution of 411 VRE
and vancomycin-susceptible Enterococcus faecium iso-
lates, recovered from human and nonhuman sources and
community and hospital reservoirs in 5 continents, identi-
fied a genetic lineage of E. faecium (complex-17) that has
spread globally. This lineage is characterized by 1) ampi-
cillin resistance, 2) a pathogenicity island, and 3) an asso-
ciation with hospital outbreaks. Complex-17 is an example
of cumulative evolutionary processes that improved the rel-
ative fitness of bacteria in hospital environments.
Preventing further spread of this epidemic E. faecium sub-
population is critical, and efforts should focus on the early
disclosure of ampicillin-resistant complex-17 strains.
T
he emergence of vancomycin-resistant enterococci
(VRE) followed a worst-case scenario for nosocomial
pathogens: the first VRE isolates that harbored the vanA
transposon were identified in 1987 in Europe (1,2), and
within 10 years VRE represented >25% of enterococci
associated with bloodstream infections in hospitalized
patients in the United States (3).
Enterococci are normal inhabitants of the gastrointesti-
nal tract of humans and animals. Two species cause most
enterococcal infections, Enterococcus faecalis and E. fae-
cium. The relative importance of E. faecium as a pathogen
has increased with the occurrence of high-level resistance
to multiple antimicrobial drugs, such as ampicillin and
vancomycin (4). The rapid increase of vancomycin resist-
ance compromises physicians’ ability to treat infections
caused by many of these strains because often no other
antimicrobial drugs are available. The epidemiology of
VRE infection differs between Europe and the United
States. In Europe, VRE are frequently isolated from farm
animals, which have been associated with the abundant use
of avoparcin as a growth promoter in the agricultural
industry, until it was banned in 1997 (5). The reported
prevalence of VRE in hospitals has been low, but increas-
ing rates (>10%) in stool and clinical samples were report-
ed recently (6–9). In the United States, avoparcin was
never approved for use in agriculture, and neither were any
other glycopeptides; consequently, VRE have not been
found in animals or healthy persons. However, nosocomi-
al VRE infection and transmission have occurred much
more frequently in the United States. Recent reports have
documented, in hospitalized patients, horizontal transfer of
the vanA gene from vancomycin-resistant E. faecalis to
methicillin-resistant Staphylococcus aureus (MRSA), cre-
ating MRSA with high-level resistance to vancomycin
(10–13). Nosocomial spread of VRE may therefore create
a reservoir of mobile resistance genes for other, more vir-
ulent, nosocomial pathogens. Without extensive control
measures, large-scale emergence of vancomycin-resistant
S. aureus (VRSA) may be the next stage in the global cri-
sis of antimicrobial resistance.
The existence of VRE in different ecologic niches com-
plicates the understanding of its epidemiology. Although
previous molecular epidemiologic studies on limited num-
bers of strains suggested host specificity and overrepresen-
tation of certain clones in hospital outbreaks (14,15), these
studies did not elucidate the patterns of evolutionary
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ture of 411 VRE and vancomycin-susceptible E. faecium
(VSE) isolates by using multilocus sequence typing
(MLST), explored the evolutionary origin of epidemic iso-
lates associated with documented hospital outbreaks and
other isolates, and assessed the association with ampicillin
resistance and the presence of a recently discovered puta-
tive pathogenicity island (PAI) in E. faecium (16).
Materials and Methods
The strain collection included 5 categories of VRE and
VSE: 1) 96 animal surveillance (bison, calves, cats, dogs,
ostriches, poultry, pigs, rodents) isolates (43 VRE, 53
VSE) from 7 countries in Africa and Europe; 2) 57 epi-
demiologically unrelated community surveillance isolates
(20 VRE, 37 VSE) from nonhospitalized persons from 7
countries in Australia and Europe; 3) 64 epidemiologically
unrelated surveillance (fecal) isolates (45 VRE, 19 VSE)
from hospitalized patients not linked to hospital outbreaks
from 9 countries in Australia, Europe, and North and South
America; 4) 162 epidemiologically unrelated hospital iso-
lates (43 VRE, 118 VSE, 1 not determined) from clinical
specimens (blood, pus, and urine) from 17 countries in
Africa, Australia, Europe, and North and South America;
and 5) 1 strain from each of 32 different documented hos-
pital outbreaks (28 VRE, 4 VSE) in 10 countries in
Australia, Europe, and North and South America (W.
Grubb and D. Jonas, pers. comm.; 15,17–23).
We determined vancomycin susceptibilities for 410 iso-
lates and ampicillin susceptibilities for 381 isolates by
using standard agar dilution methods according to NCCLS
guidelines. Isolates with MIC >16 µg/mL for ampicillin
and  >8  µg/mL for vancomycin were considered to be
resistant. In total, 394 strains were screened for the esp
gene with primer sets and amplification conditions
described previously (24). Independent and combined
effects of virulence and resistance markers on the abun-
dance of complex-17 were estimated by using multiple
logistic regression analysis (Stata 7.0, StataCorp LP,
College Station, TX, USA).
MLST was carried out with a standard set of primers
that amplify the 7 genes included in the E. faecium MLST
scheme (14). Information on these loci, the latest set of
primers, amplification conditions, and details of all iso-
lates are available on the MLST Web site (http://efaecium.
mlst.net).
The eBURST program was used to assess the genetic
relationships of genotypes, to assign isolates to genetic
complexes, and to study patterns of evolutionary descent
of isolates within a complex (25). Complexes were identi-
fied by using the stringent (6/7 shared alleles) group defi-
nition with 1,000 bootstrap replicates. The BLAND
program was used to examine the relationship between
pairwise allelic differences and nucleotide sequence differ-
ences (26). If genetic diversity in E. faecium is mainly the
result of accumulated point mutations, then recently
diverged strains will have a high level of similarity in both
their allelic profiles as well as in the nucleotide sequence
of the nonidentical alleles, which results in a positive cor-
relation between the number of nucleotide differences in
nonidentical alleles and the number of allelic differences.
However, such a trend will be absent when recombination
plays an important role in generating the genetic diversity,
since nonidentical alleles of closely related isolates can
differ at multiple nucleotide sites.
To assess the effect of recombination on the population
structure of E. faecium in more detail, the topologies of the
7 MLST gene trees were compared by using the
Shimodaira-Hasegawa test (27). Briefly, maximum likeli-
hood trees for each MLST gene were obtained under a
general time-reversible model, with a proportion of invari-
ant sites and rate heterogeneity among sites assuming a
discrete gamma distribution with 8 categories (GTR+I+Γ
model). PAUP* 4.0b10 was used to obtain the maximum
likelihood trees by using a neighbor-joining starting tree
followed by tree-bisection reconnection branch swapping
(28). For a given gene, the Shimodaira-Hasegawa test
compares the difference in log likelihoods of competing
tree topologies. A null distribution of differences in log
likelihoods was obtained by 1,000 replicates of nonpara-
metric bootstrapping of reestimated log likelihoods. We
conducted 107 Shimodaira-Hasegawa tests for each MLST
gene by comparing the 7 MLST gene trees and 100 ran-
dom trees separately generated for each of the MLST
genes. In a clonal population, the different MLST house-
keeping genes have similar tree topologies, but with
recombination, the different genes may have different tree
topologies that may fit random trees better.
Associations between ampicillin resistance, presence of
a novel putative E. faecium PAI, and genetic clustering in
complex-17 were described by linear logistic regression
models: log odds = b0 + b1x1 + b2x2 + b3x3 + … + bixi. Log
odds denotes the natural logarithm of the proportion of
samples from an epidemiologic group belonging to com-
plex-17, bi denotes the parameter estimated by maximum
likelihood methods and xi the level of exposure, e.g., 0 and
1 for ampicillin resistance, vancomycin resistance, and the
presence of PAI and 0–4 for the epidemiologic source of
isolates: animal surveillance, community surveillance,
hospital surveillance, clinical sample, and hospital out-
break, respectively.
Results
Identification of Clonal Lineages
MLST of 411 E. faecium isolates resulted in 175
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the eBURST algorithm (25) showed 1 large complex of
genetically related types. ST-22 was the primary founder;
3 minor complexes had ST-1, -69, and -94 as primary
founders; 6 complexes had only 2 or 3 STs; and 57 single-
tons were not linked to the aforementioned complexes
(Figure 1). Within complex-22, ST-17 represents an impor-
tant secondary founder of a distinct branch designated
complex-17.
Selective Advantage of the Successful 
Hospital-adapted Complex-17
In all, 142 of 411 isolates belonged to complex-17, with
a gradual increase in proportion among animal isolates
(1/96), human community isolates (3/57), human hospital
surveillance isolates (15/64), and human clinical isolates
(95/162), to hospital-outbreak isolates (28/32) (Table 1).
Ampicillin resistance, presence of the E. faecium PAI (16),
and genetic clustering in complex-17 were strongly associ-
ated (Table 2).
When controlling for individual and combined effects
of ampicillin resistance, presence of PAI, and vancomycin
resistance, we can show that 1) the loglinear assumption
holds for all effect parameters, and linear models describe
the observed frequencies without substantial loss of good-
ness of fit; 2) individual genetic markers exert an inde-
pendent and multiplicative effect; and 3) all genetic
markers combined explain ≈48% of the category-specific
abundance of complex-17 (Figure 2). The effect of van-
comycin resistance did not increase the explanatory value
of the model, owing to the fact that determinants for van-
comycin resistance could be found in equal proportions
within and outside of complex-17, likely a result of
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Figure 1. Clustering of 175 sequence types representing 411 iso-
lates with eBURST (25). This algorithm identifies the founder of a
complex or genogroup of related sequence types (ST) and subse-
quent patterns of evolutionary descent. The primary founder, indi-
cated in blue, of a complex is defined as the ST with the largest
number of single locus variants (SLVs). Larger complexes may
contain secondary founders of additional lineages that have a
number of SLVs of their own. These secondary founders are indi-
cated in yellow. Numbers correspond to ST numbers. The area of
each circle corresponds to the number of isolates of the ST. All
complexes (major and minor) are shown. In addition, 57 STs did
not group into any of the complexes and were considered single-
tons (STs 13, 15, 30, 31, 36, 37, 38, 39, 42, 51, 52, 58, 59, 62, 65,
67, 68, 70, 72, 73, 74, 83, 84, 86, 89, 95, 96, 98, 99, 100, 102, 105,
107, 108, 110, 112, 114, 116, 118, 126, 129, 131, 142, 144, 145,
152, 153, 155, 162, 163, 164, 167, 168, 169, 170, 171, 172). The
"epidemic" genetic complex-17 derived from secondary founder
ST-17 is indicated. A measurement of statistical confidence in
each of the assigned primary founders is made by a bootstrap
resampling procedure (25).The predicted primary founders of the
complexes 22, 94, 1, and 69 have a bootstrap value of 73%, 84%,
85%, and 59%, respectively.widespread horizontal transfer of vanA (Table 1). This
finding suggests that the epidemiologic success of descen-
dants of ST-17 that results in clinical infections and hospi-
tal epidemics was at least partly related to antimicrobial
resistance and the presence of putative virulence genes.
The fact that 126 of 128 isolates of complex-17 were
resistant to ampicillin and only 77 of 139 isolates of com-
plex-17 contain PAI (Table 1) suggests that E. faecium
acquired ampicillin resistance first, which resulted in a
selective advantage in hospitals, followed by the acquisi-
tion of PAI, which further facilitated transmission.
Estimates of Recombination
To assess the effect of recombination on the population
structure of E. faecium, we estimated whether single locus
variants (SLVs) from the presumed founders of complex-1,
-17, -22, -69, and -94 have arisen by point mutations or by
recombination (Table 3). Of all allelic differences between
ancestor-SLV pairs (n = 30), 22 (4 in complex-17) included
>1 nucleotide, were found in multiple clonal complexes,
and thus were most likely a result of recombination. Eight
allelic differences (2 in complex-17) included only a single
nucleotide change, were unique within the dataset, and thus
were most likely a result of mutation. Therefore, most alle-
les of SLVs in complex-17 and in the other complexes have
arisen by recombination in the initial stages of diversifica-
tion rather than by de novo point mutation. An important
role for recombination in genetic diversification in E. faeci-
um was confirmed by the lack of a positive trend between
the number of nucleotide differences in nonidentical alleles
and the number of allelic differences (Figure 3) (26). The
finding of high average numbers (≥4) of nucleotide differ-
ences in the nonidentical alleles of SLVs in the total E. fae-
cium population as well as in complex-17 also points
towards frequent recombination.
The degree of phylogenetic congruence between the 7
MLST genes was examined in a set of 24 diverse STs.
These 24 STs were separated from each other by a linkage
distance of >0.4 on a UPGMA (unweighted pair-group
method with arithmetic mean) tree constructed from the
pairwise comparisons of their allelic profiles (data not
shown) and included the primary founders of CC1 (ST1),
CC22 (ST22), CC69 (ST69), and CC94 (ST94); secondary
founders of important subgroups complex-5 (ST5) and
complex-17 (ST17); 1 ST(ST76) belonging to a small com-
plex of 3 STs; and 17 singletons (STs 15, 38, 39, 54, 67, 74,
83, 84, 89, 96, 98, 99, 101, 107, 118, 142, 163). The results
of the congruence analysis presented in Table 4 show that
25 (60%) of 42 of the pairwise comparisons of the 7 MLST
loci were incongruent. Of the 7 genes, atpA is the most
incongruent. This analysis confirms that recombination
played a substantial role in the evolution of E. faecium.
Discussion
Nosocomial VRE, which rapidly emerged in the United
States in the 1990s after their initial discovery in Europe,
are found in increasing rates in hospitals in Europe, Asia,
and South America (5–7,9,23,29,30). The data presented in
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Figure 2. Relative abundance of complex-17 in various sampled
categories and proportion increase explained by combined effect
of 3 parameters. 0, animal surveillance samples; 1, human com-
munity surveillance samples; 2, human hospitalized patient sam-
ples; 3, human clinical samples; 4, hospital outbreak samples;
amp, ampicillin resistance; PAI, pathogenicity island; gly, gly-
copeptide resistance.this study show that most of these hospital-derived VRE
are part of a single clonal lineage. This lineage, designated
complex-17 after its presumed founder ST-17, represents
most hospital outbreak and clinical isolates, apparently
because it successfully adapted to hospital environments.
The >400 strains analyzed in this study were selected
from a large representative collection of 2,000 E. faecium
isolates. A wide variety of sources were used as selection
criteria: hospital-associated outbreaks; clinical samples
and stool samples from hospitalized patients, healthy per-
sons, and animals; and a wide geographic distribution (21
countries on 5 continents).
Complex-17 probably evolved from the primary E. fae-
cium ancestor ST-22 through a combination of mutation
and recombination. The following observations suggest
that recombination has been especially important in the
genetic diversification of the E. faecium population: 1)
within clonal complexes, most SLVs (73%) have arisen by
recombination rather than point mutations; 2) no positive
correlation exists between the degree of allelic diversity
and the number of nucleotide differences in nonidentical
alleles; and 3) most (60%) of the comparisons of MLST
gene tree topologies were incongruent. 
Exploitation of a novel ecologic niche as hospital set-
tings by E. faecium ST-17 often starts with adaptive
changes (31). On the basis of our findings, we postulate
that ST-17 acquired ampicillin resistance and a novel puta-
tive PAI. This amplifying selective process in which vari-
ants with a selective advantage can more easily acquire
additional adaptive mechanisms has been called “genetic
capitalism” (32). After successfully exploiting the hospital
environment, ST-17 increased in frequency to become the
dominant clone. Genetic diversification over time finally
resulted in a meroclone, complex-17, of highly related
genotypes, fully adapted as a nosocomial pathogen, that
has spread globally (Figure 4). In addition, E. faecium STs,
predominantly ST-78, belonging to complex-17, have
recently also been found in the Republic of South Korea
(K.S. Ko and J.-H. Song, pers. comm.). Considering the
short period in which multiresistant E. faecium emerged as
a nosocomial pathogen (33), complex-17 represents the
first globally dispersed nosocomial-adapted clonal lineage.
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complex-17 is still detectable within the E. faecium popu-
lation, which suggests that the emergence of this complex
is relatively recent.
The existence of epidemic clones, even in recombining
populations, is also seen in other bacterial species (34,35).
However, the evolution of a single epidemic and clinically
relevant genetic complex, as seen with E. faecium, differs
from the evolution of other gram-positive pathogens like
Streptococcus pneumoniae and Staphylococcus aureus. In
S. pneumoniae, pandemic clones such as ST81, ST90, and
ST156 represent major invasive and multidrug-resistant
isolates that have spread globally (36). The allelic profiles
of these clones, however, are highly diverse, which sug-
gests that they are genetically unrelated and do not consti-
tute a single genetic lineage, as does E. faecium.
Furthermore, the serotype of S. pneumoniae seems a more
important marker of invasiveness than the overall geno-
type (37). In S. aureus isolates, major pandemic MRSA
clones that are responsible for most hospital-acquired
infections are found in multiple genetically unrelated line-
ages, though most previously identified pandemic clones
are found in clonal complex 8 (38,39). Therefore, the
genetic diversity of major epidemic clones as seen in S.
pneumoniae or S. aureus may not have yet emerged in E.
faecium epidemic populations.
Stress-inducing conditions in hospitals, such as antimi-
crobial drug use, may have favored the selection of an ente-
rococcal subpopulation, complex-17, with enhanced
antibacterial resistance, virulence, and ability to spread.
Whether reducing antimicrobial selection pressure in hos-
pitals will reestablish a susceptible and less transmissible
enterococcal population is unknown and will at least part-
ly depend on the relative fitness costs of sustaining antimi-
crobial resistance and virulence determinants in E.
faecium. Furthermore, the hospital-adapted complex-17
has rapidly spread globally during the last 2 decades.
Subsequent acquisition of vanA- or vanB- containing trans-
posons by horizontal gene transfer resulted in VRE with
pandemic potential. Rapid diagnosis of complex-17 strains
based on multiple locus variable number of tandem repeat
analysis (MLVA) may help control its spread (40). Whether
this effort will be successful depends on the level of com-
plex-17 endemicity in the hospital. In many European
countries, a relatively large community reservoir of VRE
exists, a result of the massive use of the antimicrobial drug
avoparcin as a growth promoter, while in general the preva-
lence of hospital-adapted (complex-17) VRE is much
lower. In such a setting, hospital transmission of  isolates
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Figure 3. Sequence diversity versus allelic diversity. The average
number of nucleotide (nt) differences in nonidentical alleles for all
pairwise comparisons of the 178 Enterococcus faecium sequence
types (STs), and the 15 STs belonging to complex-17 was calculat-
ed separately for allelic profiles that differ in 1–7 alleles. This com-
putation shows no positive correlation between the number of
nucleotide differences and allelic differences, which suggests that
recombination has played an important role in the genetic diversi-
fication in E. faecium, including the STs that constitute complex-17.
Figure 4. Global distribution of complex-17 isolates. Red circles
indicate cities where complex-17 isolates were recovered.
Numbers indicate epidemiologic sources: 1, animal isolates; 2,
human community surveillance isolates; 3, surveillance (feces)
isolates from hospitalized patients; 4, human clinical isolates; 5,
isolates from documented hospital outbreaks. Numbers of isolates
are indicated in parentheses.belonging to complex-17 can be halted by using a fast
genotyping scheme like MLVA to discriminate between
hospital-adapted (complex-17) and community E. faecium
strains followed by strict infection control measures. The
combination of infection control measures plus genotyping
controlled an outbreak of VRE in a Dutch hospital (41).
Establishing nosocomial co-endemicity of VRE and
MRSA will facilitate the horizontal transfer of vanA- or
vanB- containing transposons, transforming MRSA into
VRSA, with implications for patient care. Until now, 3
sporadic cases of vanA-induced VRSA have been reported
in the United States in 2002 and 2004. Spread of mul-
tidrug-resistant  E. faecium strains and their resistance
genes will have serious implications for health care, and
control efforts should focus on early detection of E. faeci-
um isolates belonging to complex-17. 
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